Senopsys and Patheon collaborate to develop palatable drug products

---

Senopsys LLC, signs a collaboration agreement with Patheon Inc., a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. Through this collaboration, Senopsys clients will have access to prototype drug formulations manufactured by Patheon and Patheon will be able to offer its clients taste assessment and optimization services.

"The combination of Senopsys' significant expertise in taste assessment and optimization with our broad development capabilities will provide an excellent platform for supporting our clients with additional solutions for their drug products requiring taste masking," said Dr. Shabbir Anik, Patheon's president of Global Pharmaceutical Development Services. "We have a number of clients who are interested in developing palatable dosage forms to support pediatric regulatory requirements for investigational new drugs and life cycle management initiatives for approved drugs. We look forward to working with Senopsys to develop palatable products that meet the needs of diverse patient populations."

A drug product's aesthetics - aroma, flavor, texture, mouthfeel - can have a dramatic effect on patient compliance, health outcomes and product sales. Senopsys uses proprietary sensory assessment and formulation tools to develop palatable drug products. The company quantifies the taste masking challenge of drug substances, measures the palatability of prototypes and optimizes the sensory characteristics of drug products to meet the needs of diverse patient populations. Patheon offers a full range of formulation and analytical development, and clinical supplies manufacturing and process optimization capabilities. The company can quickly and cost-effectively manufacture small-scale batches of prototype drug formulations under Good Manufacturing Practices (GMP) guidelines.

"This collaboration with Patheon enhances Senopsys' ability to conduct taste assessment and optimization studies that require the use of GMP materials," said Jeff Worthington, founder and president of Senopsys. "With Patheon's development and manufacturing capabilities and Senopsys' taste optimization expertise, our companies will be able to provide our clients with expanded options for accelerating the clinical and commercial development of their drug products."